GLP-1 cardiovascular benefits: the story beyond weight loss
Why researchers think these drugs do something for the heart that weight loss alone does not explain.
TL;DR
- The SELECT trial reported semaglutide cut major heart events by about 2 in 100 patients over roughly three years, compared with placebo.
- The risk drop showed up earlier than the full weight loss, hinting at effects on inflammation and blood vessel biology.
- The branded product Wegovy has an FDA cardiovascular indication; compounded semaglutide does not.
What it is
GLP-1 (in plain English: a gut hormone called glucagon-like peptide-1 that helps regulate appetite and blood sugar) is the target of a drug class that includes semaglutide and tirzepatide. These medicines are best known for weight loss. Recent trials show they also act on the cardiovascular system — the heart and blood vessels — in ways that look independent of the pounds patients lose (NEJM SELECT, 2023).
How it works
Think of inflammation as low-grade smoke inside your blood vessels. Over decades, that smoke damages the vessel walls and raises the risk of a heart attack. GLP-1 receptor agonists (in plain English: drugs that activate the receptor for the GLP-1 hormone) appear to lower that smoke. They reduce inflammatory markers, improve how the vessel lining (the endothelium) controls blood flow, and lower blood pressure modestly. Weight loss helps too — but the trial data suggests the drug itself is doing some of the work.
Who asks about it
People come to this topic when they have heard GLP-1 medicines called “the next aspirin for the heart.” They want to know whether the benefit is real, whether it depends on losing weight, and whether the same logic applies to compounded versions.
What the research says
The SELECT trial randomized 17,604 adults with overweight or obesity and prior cardiovascular disease. Half received semaglutide 2.4 mg weekly. Half received placebo. After about 40 months, the rate of cardiovascular death, non-fatal heart attack, or non-fatal stroke fell from 8 in 100 to 6 in 100 (NEJM, 2023). The curves separated within months — before peak weight loss. That timing is why researchers think part of the benefit is independent of weight. In March 2024 the FDA expanded Wegovy’s label to include reducing major cardiovascular events in eligible patients (FDA, 2024).
What to know before considering it
The cardiovascular indication applies to the branded product, not to compounded versions. Side effects in SELECT mirrored prior trials: nausea, gastrointestinal symptoms, and gallbladder events were more common with semaglutide. The trial enrolled patients with established cardiovascular disease; the data does not automatically extend to younger or healthier populations. Compounded GLP-1 products remain the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Any GLP-1 therapy requires a licensed clinician evaluation.
The Halftime POV
The cardiovascular story turns GLP-1 medicines from “weight-loss shots” into something closer to metabolic therapy. For patients in their second half — when heart risk starts to compound — that distinction matters. We share what the trial data actually shows, what it does not show, and which version of the medicine carries which indication.
Related reading:
- GLP-1: what this gut hormone actually does
- The SELECT trial, summarized for non-cardiologists
- What happens to cardiovascular risk when you stop GLP-1 therapy
- How semaglutide activates GLP-1 receptors
FAQ
Q: Do GLP-1 drugs really protect the heart? A: The SELECT trial, published in the New England Journal of Medicine in 2023, reported that semaglutide reduced the combined rate of cardiovascular death, non-fatal heart attack, and non-fatal stroke by about 2 in 100 patients over roughly three years compared with placebo, in adults with overweight or obesity and pre-existing cardiovascular disease.
Q: Is the cardiovascular benefit just from losing weight? A: Researchers think not. The risk reduction appeared earlier than the full weight-loss effect, which suggests the drug acts on inflammation and blood vessel biology directly, in addition to weight.
Q: Is compounded semaglutide FDA-approved for cardiovascular protection? A: No. Only the branded product Wegovy carries an FDA indication for reducing major adverse cardiovascular events in eligible patients. Compounded semaglutide is prepared by state-licensed 503A pharmacies from FDA-approved active pharmaceutical ingredients and is not itself FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
